Medical education
Smouldering COVID-19 XBB.1.5. subvariant pneumonitis: a case report
Sara Davison,
Tanmay Kanitkar, Dimitrios Menouhos, Thomas Ewin, Catherine S Marshall, Peter Boan,
Sonja Janson,
Corresponding Author
Sara Davison
Royal Darwin Hospital, Darwin, NT
Search for more papers by this authorPeter Boan
Fiona Stanley Hospital, Perth, WA
PathWest Laboratory Medicine WA, Perth, WA
Search for more papers by this authorSara Davison,
Tanmay Kanitkar, Dimitrios Menouhos, Thomas Ewin, Catherine S Marshall, Peter Boan,
Sonja Janson,
Corresponding Author
Sara Davison
Royal Darwin Hospital, Darwin, NT
Search for more papers by this authorPeter Boan
Fiona Stanley Hospital, Perth, WA
PathWest Laboratory Medicine WA, Perth, WA
Search for more papers by this authorFirst published: 05 August 2024
No abstract is available for this article.
References
- 1Uraki R, Ito M, Kiso M, et al. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Infect Dis 2023; 23: 402-403.
- 2Liebers N, Speer C, Benning L, et al. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood 2022; 139: 142-147.
- 3Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ March 2, 2022: e068632; https://doi.org/10.1136/bmj-2021-068632.
- 4Communicable Diseases Genomics Network. Variants of concern. 2023. https://www.cdgn.org.au/variants-of-concern (viewed Feb 2024).
- 5Huygens S, Hofsink Q, Nijhof IS, et al. Hyperimmune globulin for severely immunocompromised patients hospitalized with Coronavirus disease 2019: a randomized, controlled trial. J Infect Dis 2023; 227: 206-210.
- 6Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood 2022; 140: 2773-2787.
